Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05029596 · ClinicalTrials.gov registry record · Early Phase 1
Heparin Versus Normal Saline in Peripherally Inserted Central Catheter Lines
A Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 142
- Enrollment target
NCT05029596: Completed Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
NCT05029596 is a Early Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 142 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (168% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05029596, a Early Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 142 participants
- Enrollment target
Study Summary
The study team will be performing a study comparing the use of Heparin Flushes vs. Normal Saline Flushes in making sure central lines stay open. The participants will be placed in a group to receive the University of Texas Southwestern Medical Center (UTSW) Standard of Care (control group) for maintaining central lines, or a group to receive Normal Saline Flushes only (experimental group) to keep their central line open. The participants electronic medical record will be reviewed by study team members for the inclusion/exclusion criteria, the participants central line will be assessed by an 11 Blue BMT nurse every 12 hours, and they may be asked questions regarding their medical history during their stay on 11 Blue BMT. If a participant is discharged or transferred off of the 11 Blue BMT unit, they will no longer be included in the study and their central line maintenance will return to the UTSW Standard of Care. Participants in this study may be at risk for central line occlusion (a blood clot) which could require intervention to regain the free flow of fluids and use of the central line. The study team predicts there will be no increase in the rate of line occlusion when using Normal Saline Flushes only to maintain the free flow of fluids through participants central line. The study team also hopes the results of this study will help to improve patient outcomes by decreasing risk of infection, heparin associated complications, and costs.
Primary Outcome
To determine whether or not flushing central lines with normal saline only will maintain free flow through these central lines.
Interventions
- DRUG Normal Saline Group
- DRUG Heparin Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2023-03-30 |
| Phase | Early Phase 1 |
What the finished NCT05029596 record still lists
NCT05029596 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (168% higher).
The record links to 0 conditions, and to 2 interventions - of which Normal Saline Group is the first listed.
NCT05029596 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05029596 about?
NCT05029596 is a clinical study titled "Heparin Versus Normal Saline in Peripherally Inserted Central Catheter Lines". The study team will be performing a study comparing the use of Heparin Flushes vs. Normal Saline Flushes in making sure central lines stay open. The participants will be placed in a group to receive the University of Texas Southwestern Medical Center (UTSW) Standard of Care (control group) for maint...
What is the current status of trial NCT05029596?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 142 participants. The study started on 2020-02-12. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT05029596?
The interventions under investigation include: Normal Saline Group (DRUG), Heparin Group (DRUG).
Who is sponsoring clinical trial NCT05029596?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05029596's enrollment target sits among peer trials
142 115th of 2000 higher than 1,886 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI